research use only

Mesna

Name: Mesna
SKU: S1735
Availability: InStock
Rating: 5 (9 reviews)

Cat.No.S1735

Mesna, a sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.

Chemical Structure

Molecular Weight: 164.18

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: Purity: 99.97%

99.97

Related Targets	Dyes Antineoplastic and Immunosuppressive Antibiotics ADC Cytotoxin PROTAC Selection Antibiotics for Transfected Cell Antibiotics for Mammalian Cell Culture ADC Linker Antibiotics for Plant Cell Culture PROTAC Linker Hydrotropic Agents Antibody-Drug Conjugate E3 ligase Ligand Target Protein Ligand Molecular Glues Enzyme Substrate Drug-Linker Conjugates for ADC Surfactant Chelating Agent
Related Products	BAPTA-AM Rat IgG2b isotype control-InVivo Blebbistatin Methyl-β-cyclodextrin (MβCD) AP-III-a4 (ENOblock) Carbazochrome sodium sulfonate (AC-17) Ursolic Acid Osthole 4-Methylumbelliferone (4-MU) Dioscin Ethidium bromide Sesamin Bilobalide Formononetin Hesperidin L-Mimosine Carbenoxolone Sodium Vitexin N6022 Dp44mT Chlorogenic Acid Sphingosine Chrysin Coenzyme Q10 (CoQ10) Spermine Tetrahydrochloride 2-NBDG D-Lin-MC3-DMA (MC3) Morin Hydrate Ethylenediaminetetraacetic acid Silibinin (NSC 651520)

Chemical Information, Storage & Stability

Molecular Weight	164.18	Formula	C₂H₅NaO₃S₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	19767-45-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	C(CS(=O)(=O)[O-])S.[Na+]

Solubility

In vitro
Batch:

DMSO : 32 mg/mL (194.9 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 7 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04449536	Completed	Obesity\|Drug Effect	University of Oslo\|Oslo University Hospital\|University of Oxford	November 2 2020	Phase 1
NCT05016739	Completed	Spine Surgery	AuXin Surgery SA	October 22 2018	Not Applicable
NCT00524199	Completed	End Stage Renal Disease	Lawson Health Research Institute\|Canadian Institutes of Health Research (CIHR)	March 2007	Phase 2
NCT00758667	Terminated	Implant Capsular Contracture	Vanderbilt University	January 2005	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):